Main menu

Recent Pfizer Press Releases

11/17/14 8:00am EST
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)


Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants
- - - 
Data Presented Today during American Heart Association 2014 Scientific Sessions: "Clinical Science: Special Reports" Session

Portola Pharmaceuticals (NASDAQ: PTLA), Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies.

11/17/14 2:53am EST
Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology


PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC
Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015
Updates 2014 Reported Diluted EPS Range Solely to Reflect the Transaction
Analyst Call Scheduled for 10 a.m. EST on Monday, November 17, 2014

Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.

11/13/14 11:01am EST
Novel Agreement Expands Access to Pfizer’s Contraceptive, Sayana® Press, for Women Most in Need in the World’s Poorest Countries

Collaboration will help advance progress and support global efforts to increase access to voluntary family planning information, services and contraceptives by 2020

11/12/14 8:00am EST
Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting


21 Abstracts, Including Additional Clinical Trial Data and Real-World Analyses, Add to the Body of Evidence for XELJANZ® (Tofacitinib Citrate) as a Treatment Option for Adults with Moderate to Severe Rheumatoid Arthritis
- - - 
Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus
- - - 
Phase 1 Abstracts for Two Pfizer Biosimilars in Development; Both Assets Move into Phase 3 Comparability Trials

Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts).

11/6/14 8:00am EST
Cedric “The Entertainer” Urges People with Diabetic Nerve Pain to “Step On Up” and Seek Relief

New educational program launches in honor of American Diabetes Month®

Award-winning comedian and actor, Cedric “The Entertainer,” is getting serious as part of a new program –Step On Up™ – which aims to educate people,

11/5/14 11:00am EST
Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.

10/29/14 2:44pm EDT
Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults

TRUMENBA is the First and Only Approved Vaccine in the U.S. for the Prevention of Meningococcal Meningitis B

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

10/29/14 8:30am EDT
Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder

Study Also Reinforces Existing Body of Clinical Evidence in Support of the Efficacy, Safety and Tolerability Profiles of PRISTIQ

Pfizer Inc.

10/28/14 7:00am EDT

Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2014.

10/23/14 4:05pm EDT
Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend

Board of Directors Authorizes New $11 Billion Share Repurchase Program

10/23/14 8:00am EDT
Pfizer Wins SUTENT® Patent Case In Delaware District Court

Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021.


10/17/14 4:38pm EDT
FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII

EMBEDA is the first and only approved ER morphine specifically designed to deter oral and intranasal abuse when crushed

Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved an updated label for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, abuse of EMBEDA by these routes is still possible.

10/13/14 8:00am EDT
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review

NDA Requests Approval of Palbociclib as a First-Line Therapy in Combination with Letrozole for ER+, HER2- Advanced Breast Cancer

Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA).

10/10/14 8:00am EDT
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™

Rapid and sustained response in functional antibody titers observed following single-dose administration of a novel, investigational 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults

Pfizer announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus (S. aureus) candidate vaccine (SA4Ag) in healthy adults.

10/8/14 8:30am EDT
Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer

  • Metastatic breast cancer currently affects 150,000-250,000 people in the U.S. and remains an incurable condition1,2
  • New initiative aims to expand the breast cancer conversation to be more inclusive of metastatic disease

This October, Pfizer Inc. is uniting with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer. This comes after a first-of-its-kind survey commissioned by Pfizer revealed that many people know little to nothing about metastatic breast cancer – the most advanced stage of breast cancer (Stage IV), in which cancer has spread beyond the breast to other organs in the body.2,3

10/8/14 8:00am EDT
Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine

Data From This Study Will Be Presented At IDWeek 2014™ In Philadelphia

Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4.

9/29/14 8:00pm EDT
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

Agreement to Combine Kyowa Hakko Kirin’s Anti-CCR4 Antibody Mogamulizumab and Pfizer’s investigational 4-1BB agonist (PF-05082566) in Clinical Study

Pfizer Inc.

9/25/14 8:00am EDT
Pfizer Completes Acquisition Of InnoPharma

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.